Company Overview and News

 
Telco industry veteran Kevin Russell takes top job at Vocus

2018-05-21 theage.com.au
Troubled telco Vocus Group has appointed industry veteran Kevin Russell as group managing director and chief executive, replacing former boss Geoff Horth who stood down in February after "disappointing" financial results.

 
Telco industry veteran Kevin Russell takes top job at Vocus

2018-05-21 smh.com.au
Troubled telco Vocus Group has appointed industry veteran Kevin Russell as group managing director and chief executive, replacing former boss Geoff Horth who stood down in February after "disappointing" financial results.

 
Vocus NZ head Mark Callander bumped up to boardroom

2018-05-21 nzherald.co.nz
Vocus Group's New Zealand chief Mark Callander will join the Australasian telecommunications group's board later this month, joining newly appointed managing director Kevin Russell.

 
Mansfield takes Vocus chair in latest leadership shake-up

2018-03-07 theage.com.au
Vocus Group has announced yet another change to its leadership team, with Vaughan Bowen leaving the struggling telco after only five months as chairman.

 
Vocus chief executive exits after tumultuous tenure at the telco

2018-02-26 abc.net.au
Telco company Vocus is searching for a new chief executive just days after downgrading its earnings guidance.

 
Vocus Group announces restructure

2018-01-14 theage.com.au
Vocus Group has divided the enterprise and wholesale divisions of its Australian business into separate operating segments, in a bid to restore shareholder value.

 
Vocus Group announces restructure

2018-01-14 smh.com.au
Vocus Group has divided the enterprise and wholesale divisions of its Australian business into separate operating segments, in a bid to restore shareholder value.

 
Australia's Vocus puts Kiwi business up for sale

2017-10-23 nzherald.co.nz
ASX-listed Vocus Group plans to sell its New Zealand assets, which include the Orcon and CallPlus retail businesses, by the end of June next year.

 
Vocus adds heavy hitters in board renewal

2017-10-03 businessnews.com.au
Vocus Communications has appointed former M2 Group boss Vaughan Bowen and former Telstra chairman Bob Mansfield to lead a board tasked with turning around the faltering business.

 
Vocus receives second $2.2b takeover offer as Affinity enters fray

2017-07-11 theage.com.au
Australia's fourth-biggest telco, Vocus Group, has received a second takeover offer of $3.50 a share after  Asia-based private equity firm Affinity Equity Partners entered the fray. 

 
Vocus receives second $2.2b takeover offer as Affinity enters fray

2017-07-11 smh.com.au
Australia's fourth-biggest telco, Vocus Group, has received a second takeover offer of $3.50 a share after  Asia-based private equity firm Affinity Equity Partners entered the fray. 

 
Markets Live: Seller fatigue

2017-06-07 theage.com.au
Shares are set for a cautiously positive start as investors regroup following yesterday's heavy losses and as oil bounces overnight, ahead of GDP data.

 
Markets Live: Seller fatigue

2017-06-07 smh.com.au
Shares are set for a cautiously positive start as investors regroup following yesterday's heavy losses and as oil bounces overnight, ahead of GDP data.

 
Vocus NZ earnings soar with CallPlus acquisition

2017-02-22 nzherald.co.nz
Vocus Communications' New Zealand earnings soared in the latter half of 2016 as the ASX-listed telecommunications company benefited from the addition of CallPlus when it merged with M2 Group, and it is targeting bundled power package as a means to drive growth on this side of the Tasman.

 
Vocus issues first guidance as combined business

2016-11-28 theage.com.au
Vocus Communications has issued its first guidance for 2016-17 bringing recent acquisitions Nextgen, M2 Group and Amcom under the one umbrella.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...